Supplementary Table 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 3. Serious Adverse Events.
Authors: Stefan G. van Ravensteijn, Jacco J. de Haan, Hans Gelderblom, Maikel J.L. Nederkoorn, Melissa H.S. Hillebrandt-Roeffen, Mark A.J. Gorris, Tessa J.J. de Bitter, Annemarie Boleij, Alem Gusinac, Thomas H.A. Ederveen, Uta E. Flucke, Johannes J. Bonenkamp, Frank M. Speetjens, Suzanne E.J. Kaal, Minke Smits, Kalijn F. Bol, Carla M.L. van Herpen, Yvonne M.H. Versleijen-Jonkers, Ingrid M.E. Desar
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413906898